ReviewCureus2026
Current and Emerging Strategies for the Prevention of Respiratory Syncytial Virus (RSV) Infections: A Comprehensive Review of Vaccines and Antibody Therapies.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Blocking two host receptors is better than one: Insights from RSV infection in human respiratory organoids.Molecular therapy. Nucleic acids · 2026Article
- A comprehensive look at Respiratory Syncytial Virus (RSV): from pathogenesis to prevention.Tropical diseases, travel medicine and vaccines · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Respiratory syncytial virus (RSV) exerts a profound influence on public health worldwide, particularly affecting vulnerable groups such as infants, the elderly, and those with compromised immune systems. Furthermore, RSV presents notable challenges in vaccine development and distribution, underscoring the importance of ensuring equitable access to preventative solutions. The virus's capacity to evade immune defenses complicates both treatment and prevention, emphasizing the critical need for continued research and the implementation of effective vaccination programs. RSV vaccines, such as Arexvy, Abrysvo, and mRESVIA, as well as monoclonal antibodies, such as nirsevimab and clesrovimab, have been developed using platforms like mRNA technology, protein subunits, and viral vectors, each with unique mechanisms of action, immunogenic properties, and safety profiles. Clinical research demonstrates that mRNA-based vaccines, protein-based vaccines, viral vector vaccines, and monoclonal antibodies effectively reduce hospital admissions and the risk of lower respiratory tract disease from RSV. However, RSV vaccine efficacy varies across age groups due to differences in immune system development and response. RSV vaccine implementation requires rigorous safety monitoring due to concerns over vaccine-associated enhanced respiratory disease (VAERD) and rare adverse effects, such as Guillain-Barré Syndrome (GBS). Comprehensive post-market surveillance and ongoing pharmacovigilance are vital to refining vaccine strategies, ensuring safety for high-risk groups like infants, the immunocompromised, and the elderly, while confirming that the benefits outweigh potential risks. Healthcare providers play a crucial role in advocating for RSV vaccination, and the development of universal RSV vaccines has become a research priority, aiming to deliver broad protection across various populations and strains. As technological advancements continue, the future of preventative measures, including vaccines and monoclonal antibodies, is poised to bring transformative solutions, ultimately reducing the burden of RSV and improving public health worldwide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.